NasdaqGS - Delayed Quote • USD
Gilead Sciences, Inc. (GILD)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:55 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 23 | 23 | 19 | 29 |
| Avg. Estimate | 1.69 | 1.91 | 3.93 | 7.3 |
| Low Estimate | 1.41 | 1.73 | 3.46 | 6.61 |
| High Estimate | 2.05 | 2.25 | 4.64 | 8.25 |
| Year Ago EPS | 1.34 | 2.29 | 6.72 | 3.93 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 20 | 20 | 29 | 29 |
| Avg. Estimate | 6.77B | 7.07B | 27.5B | 27.98B |
| Low Estimate | 6.56B | 6.92B | 27.11B | 27.24B |
| High Estimate | 7B | 7.24B | 28.04B | 28.93B |
| Year Ago Sales | 6.6B | 6.8B | 27.12B | 27.5B |
| Sales Growth (year/est) | 2.70% | 3.90% | 1.40% | 1.70% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 1.64 | 1.92 | 1.76 | -1.49 |
| EPS Actual | 1.34 | 2.29 | 1.72 | -1.32 |
| Difference | -0.3 | 0.37 | -0.04 | 0.17 |
| Surprise % | -18.30% | 19.30% | -2.30% | 11.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.69 | 1.91 | 3.93 | 7.3 |
| 7 Days Ago | 1.59 | 1.8 | 5.67 | 6.86 |
| 30 Days Ago | 1.57 | 1.78 | 6.55 | 6.86 |
| 60 Days Ago | 1.71 | 1.93 | 7.1 | 7.44 |
| 90 Days Ago | 1.65 | 1.84 | 6.64 | 6.97 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 3 |
| Up Last 30 Days | 2 | 3 | 1 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 7 | 3 |
Growth Estimates
| CURRENCY IN USD | GILD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 26.10% | -- | -- | 5.40% |
| Next Qtr. | -16.60% | -- | -- | 10.90% |
| Current Year | -41.50% | -- | -- | 4.50% |
| Next Year | 85.80% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 5.38% | -- | -- | 10.94% |
| Past 5 Years (per annum) | 1.66% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | TD Cowen: Buy to Buy | 4/26/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 4/26/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 4/26/2024 |
| Reiterates | Needham: Hold | 4/26/2024 |
| Upgrade | HSBC: Reduce to Hold | 4/24/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 4/19/2024 |
Related Tickers
BMY Bristol-Myers Squibb Company
44.85
+0.34%
BIIB Biogen Inc.
208.90
+3.18%
ABBV AbbVie Inc.
159.62
-4.58%
MRK Merck & Co., Inc.
131.20
+0.37%
PFE Pfizer Inc.
25.40
+0.55%
AZN AstraZeneca PLC
75.17
+0.19%
AMGN Amgen Inc.
269.98
+0.22%
JNJ Johnson & Johnson
146.14
-0.46%
SNY Sanofi
49.13
-0.47%
LLY Eli Lilly and Company
733.51
+1.19%